Compare Regeneron Pharmaceuticals Inc (REGN) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.

TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.145, down 0.17% on the day and near multi-year lows amid a prolonged bond market selloff. Technical indicators are bearish, with moving averages signaling strong selling pressure, while oversold RSI readings suggest potential for a near-term bounce. The fund continues to pay dividends, with recent payments of $0.31-$0.33 per share, but key financial ratios are unavailable as it is an ETF tracking long-term Treasury bonds.

The outlook for TLT remains heavily tied to the direction of long-term interest rates. Rising yields have pressured prices, but current levels may attract income-focused investors seeking high yields. Key risks include further Fed tightening, persistent inflation, and economic growth surprises that could extend the bond bear market. Analyst sentiment is cautious given the unfavorable rate environment.